A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
Metastatic Castration-resistant Prostate Cancer
DRUG: 177Lu-NYM032 injection
Number of Patients With Dose Limiting Toxicity (DLT), Dose limiting toxicity is determined by monitoring for adverse events following therapy., 28 days|Maximum Tolerated Dose (MTD), Maximum tolerated dose (MTD) is determined by monitoring dose-limiting toxicity and adverse events in the dosing cohorts, 28 days
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.